Trends in Healthcare Costs among People Living with HIV in Ontario, Canada, 2003-2018: Results from a Population-Based Retrospective Cohort Study

This population-based retrospective study in Ontario (2003–2018) reveals that annual mean healthcare costs for people living with HIV increased by approximately 40% driven primarily by medication expenditures, with significant cost disparities persisting among older adults, low-income residents, and those with advanced disease at diagnosis.

The Gist

Imagine the healthcare system as a massive, public library that everyone can use for free. This study is like a librarian who spent 15 years (from 2003 to 2018) tracking how much it costs to keep the "HIV section" of that library running for every single person who walks through the doors.

Here is the story of what they found, told in simple terms:

The Big Picture: The Price Tag is Rising

The researchers looked at nearly 26,000 people living with HIV in Ontario. They wanted to know: How much does it cost the public to care for one person each year?

Think of the cost like a monthly grocery bill. In 2003, the average "bill" for one person was about $12,000. By 2018, that bill had grown to about $17,000. It's not a tiny jump; it's a steady climb, much like how the price of gas or rent has gone up over the years.

The Main Ingredient: The "Medicine" Bill

If you look at what makes up that $17,000 bill, the biggest chunk is always the medication.

• The Analogy: Imagine the total cost is a giant pizza. For over a decade, the "medicine slice" has been the biggest piece, taking up anywhere from nearly half to almost two-thirds of the whole pizza.
• Because the medicine costs went up, the total bill went up right along with it. The other costs (like doctor visits or hospital stays) stayed relatively steady, but the price of the drugs drove the trend.

Who Pays the Most? (The Disparities)

The study found that the "grocery bill" isn't the same for everyone. Some groups consistently had higher costs, which usually means they needed more help or were getting it later than others.

• Older Diagnoses: People who were diagnosed at an older age had higher costs. It's like trying to fix a leaky roof after the house has been flooding for years; it's harder and more expensive than fixing it the moment you see the first drip.
• Lower Income: People living in poorer neighborhoods had higher costs. This suggests that when life is harder financially, staying healthy becomes more expensive for the system.
• Late Treatment: People whose immune systems (measured by CD4 counts) had already dropped very low before they started treatment had higher costs. This is the "leaky roof" analogy again—waiting too long to start treatment makes the eventual repair much more expensive.

The Takeaway: How to Lower the Bill

The authors aren't saying we should stop treating people. Instead, they are suggesting smart ways to keep the "library" running without breaking the bank.

1. Shop Around for Meds: They suggest using more "generic" medicines (the store-brand versions of drugs). Just like buying store-brand cereal saves money compared to name-brand cereal, this could lower the biggest slice of the pizza without changing the taste or the health benefits.
2. Negotiate Better Prices: The government can act like a savvy shopper at a bulk store, negotiating better prices for the drugs so the public doesn't have to pay full price.
3. Fix the Leaks Early: The most important lesson is that early treatment saves money. If we help people start treatment immediately after diagnosis and address social issues like poverty and housing, we stop the "leak" before the house floods. This keeps the costs down for everyone and ensures people stay healthier.

In short: Treating HIV is getting more expensive, mostly because of drug prices. But by buying smarter and treating people earlier, we can keep the costs manageable and ensure everyone gets the care they need.

Technical Summary

1. Problem Statement

The study addresses the economic sustainability of publicly funded healthcare systems in the context of the HIV epidemic. While antiretroviral therapy (ART) has transformed HIV into a manageable chronic condition, the long-term financial implications of treating a growing, aging population of people living with HIV (PLWH) remain a critical policy concern. Specifically, the study seeks to quantify the evolution of annual healthcare costs per person over a 15-year period (2003–2018) to determine if costs are escalating, identify the primary cost drivers, and analyze how these costs vary across different sociodemographic and clinical subgroups.

2. Methodology

The research employed a retrospective population-based cohort design utilizing comprehensive administrative health data from Ontario, Canada.

• Study Population: The primary cohort included 25,842 individuals living with HIV who were diagnosed and entered care between 1992 and 2018.
• Nested Cohort: A sub-cohort of 3,516 participants from the Ontario HIV Treatment Network (OHTN) Cohort Study was integrated to provide granular clinical data not available in standard administrative records (e.g., nadir CD4 counts, specific ART usage history).
• Costing Approach:
  • Annual mean healthcare costs were calculated using a validated costing algorithm.
  • All monetary values were adjusted for inflation and expressed in 2025 Canadian dollars to ensure temporal comparability.
  • The analysis adopted a publicly funded healthcare system perspective, capturing direct medical costs.
• Analytical Strategy:
  • Trend Analysis: Examined overall cost trends from 2003 to 2018.
  • Stratification: Costs were stratified by:
    • Sociodemographics: Age, sex, rurality, neighbourhood income, and immigration status.
    • Clinical Factors (Nested Cohort): Nadir CD4 count (<200 vs. ≥200 cells/µL) and history of ART use since diagnosis.
  • Cost Components: Disaggregated costs to identify specific drivers (e.g., medications vs. hospitalization).

3. Key Contributions

• Longitudinal Scope: Provides one of the most extensive longitudinal analyses of HIV-related healthcare costs in a publicly funded system, covering a 15-year period that encompasses significant shifts in treatment guidelines and drug pricing.
• Granular Cost Attribution: Moves beyond aggregate spending to identify specific cost components, confirming that medication costs are the dominant and most volatile driver of total expenditure.
• Disparity Identification: Systematically links cost variations to social determinants of health (income, immigration status) and clinical markers (nadir CD4), highlighting that higher costs are often associated with delayed care initiation and socioeconomic vulnerability.
• Policy-Relevant Forecasting: By inflating costs to 2025 values, the study offers a contemporary baseline for future budget planning and health economic modeling.

4. Key Results

• Overall Cost Trends: The annual mean healthcare cost per person increased significantly over the study period, rising from $11,963 in 2003 to $16,721 in 2018.
• Primary Cost Driver: Medication costs constituted the largest proportion of total spending throughout the study, ranging from 47.4% to 61.7%. The trend in medication costs closely mirrored the overall cost trend, indicating that drug pricing and utilization are the primary determinants of total expenditure.
• Sociodemographic Disparities: Higher annual mean costs were consistently observed in:
  • Individuals diagnosed at older ages.
  • Residents of lower-income neighbourhoods.
  • Long-term Ontario residents (Canadian-born or immigrants arriving before 1985).
• Clinical Correlates: Individuals with a nadir CD4 count <200 cells/µL (indicating advanced immunosuppression at diagnosis) incurred higher costs, likely due to the management of opportunistic infections and comorbidities associated with delayed treatment.

5. Significance and Implications

The study underscores that while HIV care is effective, it remains a substantial and growing financial burden on public health systems. The findings suggest that:

• Cost Containment Strategies: Since medication costs are the primary driver, interventions such as expanded generic substitution and strengthened price negotiations for antiretroviral drugs are essential to curb rising expenditures without compromising clinical outcomes.
• Addressing Social Determinants: The persistent cost disparities linked to income and immigration status highlight that economic inefficiencies are partly driven by delayed treatment initiation. Policies aimed at improving early diagnosis and engagement in care for marginalized populations could reduce long-term costs by preventing the progression to advanced disease stages.
• System Planning: Health policymakers must anticipate continued cost growth driven by an aging HIV population and the high cost of modern therapeutics, necessitating proactive budgeting and strategic procurement.